- Home
- RIGL vs SABR Comparison
RIGL vs SABR Comparison
Compare RIGL & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | SABR |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.6M | 627.9M |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RIGL | SABR |
|---|---|---|
| Price | $49.33 | $1.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $43.20 | $4.12 |
| AVG Volume (30 Days) | 638.4K | ★ 5.3M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2698.26 | N/A |
| EPS | ★ 6.20 | 1.41 |
| Revenue | $282,076,000.00 | ★ $3,034,040,000.00 |
| Revenue This Year | $65.53 | N/A |
| Revenue Next Year | $0.22 | $3.88 |
| P/E Ratio | $7.89 | ★ $1.16 |
| Revenue Growth | ★ 79.13 | 8.86 |
| 52 Week Low | $14.63 | $1.52 |
| 52 Week High | $52.24 | $4.63 |
Technical Indicators
Market Signals| Indicator | RIGL | SABR |
|---|---|---|
| Relative Strength Index (RSI) | 64.29 | 41.92 |
| Support Level | $43.81 | $1.57 |
| Resistance Level | $52.24 | $1.70 |
| Average True Range (ATR) | 3.35 | 0.08 |
| MACD | -0.13 | 0.01 |
| Stochastic Oscillator | 75.13 | 56.82 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company sold its growing hotel IT solutions division (9% of revenue) to TPG in 2025 for $960 million in net proceeds. Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.